CN102414212A - 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 - Google Patents

与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 Download PDF

Info

Publication number
CN102414212A
CN102414212A CN2010800184448A CN201080018444A CN102414212A CN 102414212 A CN102414212 A CN 102414212A CN 2010800184448 A CN2010800184448 A CN 2010800184448A CN 201080018444 A CN201080018444 A CN 201080018444A CN 102414212 A CN102414212 A CN 102414212A
Authority
CN
China
Prior art keywords
mmol
cyclohexyl
methoxy
indolo
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800184448A
Other languages
English (en)
Chinese (zh)
Inventor
J.A.本德
K.伊斯门
J.F.卡道
杨忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102414212A publication Critical patent/CN102414212A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2010800184448A 2009-02-26 2010-02-24 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 Pending CN102414212A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15563409P 2009-02-26 2009-02-26
US61/155,634 2009-02-26
PCT/US2010/025169 WO2010099159A1 (en) 2009-02-26 2010-02-24 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
CN102414212A true CN102414212A (zh) 2012-04-11

Family

ID=42289577

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800184448A Pending CN102414212A (zh) 2009-02-26 2010-02-24 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂

Country Status (5)

Country Link
US (1) US8143244B2 (cg-RX-API-DMAC7.html)
EP (1) EP2401280B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012519173A (cg-RX-API-DMAC7.html)
CN (1) CN102414212A (cg-RX-API-DMAC7.html)
WO (1) WO2010099159A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120329310A (zh) * 2025-04-18 2025-07-18 中国科学院成都生物研究所 一类苯并呋喃氮杂环化合物及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
KR20100126560A (ko) * 2008-03-27 2010-12-01 브리스톨-마이어스 스큅 컴퍼니 피롤리딘 융합된 인돌로벤자디아제핀 hcv ns5b 억제제
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
EP4269332A1 (de) 2022-04-26 2023-11-01 GasConTec GmbH Verfahren und anlage zur herstellung von ammoniak

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
WO2008097796A1 (en) * 2007-02-02 2008-08-14 Bristol-Myers Squibb Company Indolobenzazepine derivatives for the treatment of hepatitis c
WO2008112848A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2008112841A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US20090042860A1 (en) * 2007-08-09 2009-02-12 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000048I1 (de) 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
US7265152B2 (en) 2002-11-01 2007-09-04 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
US6745521B1 (en) * 2002-12-13 2004-06-08 Klemming Ulf Jp Gazebo
WO2004058756A1 (en) 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
CA2552584A1 (en) 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
WO2006103399A1 (en) 2005-03-31 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
WO2006121831A2 (en) 2005-05-10 2006-11-16 Merck & Co., Inc. Hiv integrase inhibitors
AU2006272521A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
WO2007059125A2 (en) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
US20070129379A1 (en) 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
WO2007143446A1 (en) 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US8178523B2 (en) 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
WO2008097796A1 (en) * 2007-02-02 2008-08-14 Bristol-Myers Squibb Company Indolobenzazepine derivatives for the treatment of hepatitis c
WO2008112848A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2008112841A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US20090042860A1 (en) * 2007-08-09 2009-02-12 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VINCENZO SUMMA,等: "Discovery of a,γ-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120329310A (zh) * 2025-04-18 2025-07-18 中国科学院成都生物研究所 一类苯并呋喃氮杂环化合物及其制备方法

Also Published As

Publication number Publication date
EP2401280B1 (en) 2013-05-01
US8143244B2 (en) 2012-03-27
US20100216774A1 (en) 2010-08-26
WO2010099159A1 (en) 2010-09-02
JP2012519173A (ja) 2012-08-23
EP2401280A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
CN101490054B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
CN101631790B (zh) 用于治疗丙型肝炎的化合物
US7521441B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101679441B (zh) 用于治疗丙型肝炎的化合物
CN101679442B (zh) 用于治疗丙型肝炎的化合物
CN101790533B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv抑制剂
CN101918410B (zh) 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
EP2401280B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101730698B (zh) 用于治疗丙型肝炎的化合物
CN101821268B (zh) 用于治疗丙型肝炎的四环化合物
CN101918412B (zh) 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物
KR20090008344A (ko) 시클로프로필 융합된 인돌로벤즈아제핀 hcv ns5b 억제제
TW201014855A (en) Compounds for the treatment of hepatitis C
TW200848058A (en) Compounds for the treatment of hepatitis C
JP2011504179A (ja) C型肝炎治療のための化合物
CN101679437B (zh) 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
CN101646674B (zh) 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物
CN101981038B (zh) 二氧戊环和二氧戊环酮稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120411